UK start­up NodThera banks a $40M round with plans to con­quer a close­ly-stud­ied in­flam­ma­to­ry tar­get

A start­up in Cam­bridge, UK called NodThera has banked a $40 mil­lion A round to dig deep­er in­to de­vel­op­ing small mol­e­cules tar­get­ing NL­RP3, a rather …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.